Showing results (41-50 of 53) with videos related to
Sort By:
Pageof 6
Cancers|April 3, 2019
TERT Promoter Mutations are Associated with Visceral Spreading in Melanoma of the TrunkSimona Osella-Abate, Luca Bertero, Rebecca Senetta, et al.International Journal of Molecular Sciences|April 30, 2021
Prognostic and Predictive Biomarkers in Stage III Melanoma: Current Insights and Clinical ImplicationsLuca Tonella, Valentina Pala, Renata Ponti, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2018
BRAF and MEK Inhibitors Increase PD-1-Positive Melanoma Cells Leading to a Potential Lymphocyte-Independent Synergism with Anti-PD-1 AntibodyMartina Sanlorenzo, Igor Vujic, Arianna Floris, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2006
Prognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous LymphomasPier Luigi Zinzani, Pietro Quaglino, Nicola Pimpinelli, et al.The Journal of Investigative Dermatology|November 9, 2020
Phenotypical Markers, Molecular Mutations, and Immune Microenvironment as Targets for New Treatments in Patients with Mycosis Fungoides and/or Sézary SyndromePietro Quaglino, Paolo Fava, Alessandro Pileri, et al.Cancer Medicine|September 27, 2016
Primary cutaneous B-cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: Comparison with current classification and definition of prognostic markersMarco Lucioni, Emilio Berti, Luca Arcaini, et al.European Journal of Cancer (Oxford, England : 1990)|August 25, 2019
Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)Paul Nathan, Paolo A Ascierto, John Haanen, et al.European Journal of Cancer (Oxford, England : 1990)|October 4, 2019
Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172)Dirk Schadendorf, Paolo A Ascierto, John Haanen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2022
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II TrialPaolo A Ascierto, Mario Mandalà, Pier Francesso Ferrucci, et al.Nature Communications|January 3, 2024
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trialPaolo A Ascierto, Milena Casula, Jenny Bulgarelli, et al.Pageof 6